Abstract
Denosumab is currently the most effective medication to delay skeletal-related events (pathologic fractures and spinal cord compression, as well as bone pain or lesions requiring palliative radiation therapy or surgery) in skelatal metastases. Denosumab reduces morbidity, delays the pain increase and improves the quality of life of the affected patients.